Search Results - "Kroiss, M"

Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study by Libé, R., Borget, I., Ronchi, C.L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., Bala, M., Tabarin, A., Beuschlein, F., Vezzosi, D., Deutschbein, T., Borson-Chazot, F., Hermsen, I., Stell, A., Fottner, C., Leboulleux, S., Hahner, S., Mannelli, M., Berruti, A., Haak, H., Terzolo, M., Fassnacht, M., Baudin, E.

“…The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic…”
Get full text

Erythropoiesis in Cushing syndrome: sex-related and subtype-specific differences. Results from a monocentric study by Detomas, M., Deutschbein, T., Tamburello, M., Chifu, I., Kimpel, O., Sbiera, S., Kroiss, M., Fassnacht, M., Altieri, B.

“…Context Cushing syndrome (CS) is associated with different hematological abnormalities. Nevertheless, conflicting data about erythropoiesis in CS have been…”
Get full text

S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study by Elhassan, Y S, Altieri, B, Berhane, S, Cosentini, D, Calabrese, A, Haissaguerre, M, Kastelan, D, Fragoso, M C B V, Bertherat, J, Al Ghuzlan, A, Haak, H, Boudina, M, Canu, L, Loli, P, Sherlock, M, Kimpel, O, Laganà, M, Sitch, A J, Kroiss, M, Arlt, W, Terzolo, M, Berruti, A, Deeks, J J, Libé, R, Fassnacht, M, Ronchi, C L

“…Objective Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for the Study…”
Get full text

Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon‐specific penetrance and changes in management during the last four decades by Mucha, L., Leidig‐Bruckner, G., Frank‐Raue, K., Bruckner, Th, Kroiss, M., Raue, F.

“…Summary Objectives We describe phaeochromocytoma (phaeo) penetrance in multiple endocrine neoplasia type 2 (MEN2) according to RET protooncogene‐specific…”
Get full text

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers by Jahn, A., Rump, A., Widmann, T.J., Heining, C., Horak, P., Hutter, B., Paramasivam, N., Uhrig, S., Gieldon, L., Drukewitz, S., Kübler, A., Bermudez, M., Hackmann, K., Porrmann, J., Wagner, J., Arlt, M., Franke, M., Fischer, J., Kowalzyk, Z., William, D., Weth, V., Oster, S., Fröhlich, M., Hüllein, J., Valle González, C., Kreutzfeldt, S., Mock, A., Heilig, C.E., Lipka, D.B., Möhrmann, L., Hanf, D., Oleś, M., Teleanu, V., Allgäuer, M., Ruhnke, L., Kutz, O., Knurr, A., Laßmann, A., Endris, V., Neumann, O., Penzel, R., Beck, K., Richter, D., Winter, U., Wolf, S., Pfütze, K., Geörg, C., Meißburger, B., Buchhalter, I., Augustin, M., Aulitzky, W.E., Hohenberger, P., Kroiss, M., Schirmacher, P., Schlenk, R.F., Keilholz, U., Klauschen, F., Folprecht, G., Bauer, S., Siveke, J.T., Brandts, C.H., Kindler, T., Boerries, M., Illert, A.L., von Bubnoff, N., Jost, P.J., Metzeler, K.H., Bitzer, M., Schulze-Osthoff, K., von Kalle, C., Brors, B., Stenzinger, A., Weichert, W., Hübschmann, D., Fröhling, S., Glimm, H., Schröck, E., Klink, B.

“…Germline variant evaluation in precision oncology opens new paths toward the identification of patients with genetic tumor risk syndromes and the exploration…”
Get full text

Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients by Arshad, U, Taubert, M, Kurlbaum, M, Frechen, S, Herterich, S, Megerle, F, Hamacher, S, Fassnacht, M, Fuhr, U, Kroiss, M

“…Objective Mitotane is used for the treatment of adrenocortical carcinoma. High oral daily doses of typically 1–6 g are required to attain therapeutic…”
Get full text

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection by Terzolo, M, Baudin, A E, Ardito, A, Kroiss, M, Leboulleux, S, Daffara, F, Perotti, P, Feelders, R A, deVries, J H, Zaggia, B, De Francia, S, Volante, M, Haak, H R, Allolio, B, Al Ghuzlan, A, Fassnacht, M, Berruti, A

“…ContextMitotane plasma concentrations ≥14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma…”
Get full text

Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature by Jurowich, C, Fassnacht, M, Kroiss, M, Deutschbein, T, Germer, C-T, Reibetanz, J

“…Adrenocortical carcinoma (ACC) is a rare endocrine neoplasm and complete resection is the only treatment with curative intent for patients with nonmetastatic…”
Get more information

PO-1892 Prediction of PTV coverage for LINAC SABR Prostate 36.25Gy/5# from OARs overlap with PTV by Kroiss, M.

Get full text

Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential by Sbiera, S, Kroiss, M, Thamm, T, Beyer, M, Majidi, F, Kuehner, D, Wobser, M, Becker, J C, Adam, P, Ronchi, C, Allolio, B, Fassnacht, M

“…Treatment options for adrenocortical carcinoma (ACC) are very limited. In other solid tumors, small vaccination trials targeting the anti-apoptotic molecule…”
Get more information

OC-0404 A BAYESIAN FRAMEWORK FOR MARKER-BASED PATIENT POSITIONING WITH A FEW PROJECTIONS IN VERY SHORT ARCS by Hoegele, W, Loeschel, R, Dobler, B, Kroiss, M, Koelbl, O, Zygmanski, P

Get full text

Localization of deformable tumors from short-arc projections using Bayesian estimation by Hoegele, W., Zygmanski, P., Dobler, B., Kroiss, M., Koelbl, O., Loeschel, R.

“…Purpose: The authors present a stochastic framework for radiotherapy patient positioning directly utilizing radiographic projections. This framework is…”
Get full text

Thymoma, myasthenia gravis, eruptions of pemphigus vulgaris and a favourable course of relapsing melanoma: an immunological puzzle by Meyer, S., Kroiss, M., Landthaler, M., Vogt, T.

Get full text

Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients by Drechsler, Christiane, MD, PHD, Schneider, Andreas, MD, Gutjahr-Lengsfeld, Lena, MSc, Kroiss, Matthias, MD, PHD, Carrero, Juan Jesús, PHD, Krane, Vera, MD, Allolio, Bruno, MD, Wanner, Christoph, MD, Fassnacht, Martin, MD

“…Background In dialysis patients, the prevalence of thyroid disorders and their impact on specific cardiovascular (CV) events and mortality are largely unknown…”
Get full text

High-dose intravenous immune globulin is also effective in linear IgA disease by Kroiss, M.M., Vogt, T., Landthaler, M., Stolz, W.

Get full text

MO-0145 Impact of the 2022 UK Consensus dose-volume constraints on national SBRT benchmark planning by Kroiss, M., Díez, P., Patel, R.

Get full text

PO-1030 Quantitative benefit of centralised quality assurance for the implementation of Lung SABR by Kroiss, M., Patel, R., Diez, P.

Get full text

Benefits of alpine mountain climate of Bavaria in patients with allergic diseases and chronic obstructive pulmonary disease: results from the AURA study by Eberlein, B, Gulyas, A, Schultz, K, Lecheler, J, Flögel, S, Wolfmeyer, C, Thiessen, K, Gass, S, Kroiss, M, Huss-Marp, J, Darsow, U, Hollweck, R, Schuster, T, Behrendt, H, Ring, J

Get full text

Neues zur systemischen Therapie des medullären Schilddrüsenkarzinoms by Fassnacht, M., Schmidmaier, R., Kroiss, M., Kreissl, M.C.

“…Zusammenfassung Hintergrund Das medulläre Schilddrüsenkarzinom ist eine sehr seltene Erkrankung (jährliche Inzidenz 2–5/Mio. Einwohner) mit variablem, aber…”
Get full text

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers by Wirth, Lori J, Sherman, Eric, Robinson, Bruce, Solomon, Benjamin, Kang, Hyunseok, Lorch, Jochen, Worden, Francis, Brose, Marcia, Patel, Jyoti, Leboulleux, Sophie, Godbert, Yann, Barlesi, Fabrice, Morris, John C, Owonikoko, Taofeek K, Tan, Daniel S.W, Gautschi, Oliver, Weiss, Jared, de la Fouchardière, Christelle, Burkard, Mark E, Laskin, Janessa, Taylor, Matthew H, Kroiss, Matthias, Medioni, Jacques, Goldman, Jonathan W, Bauer, Todd M, Levy, Benjamin, Zhu, Viola W, Lakhani, Nehal, Moreno, Victor, Ebata, Kevin, Nguyen, Michele, Heirich, Dana, Zhu, Edward Y, Huang, Xin, Yang, Luxi, Kherani, Jennifer, Rothenberg, S. Michael, Drilon, Alexander, Subbiah, Vivek, Shah, Manisha H, Cabanillas, Maria E

“…Medullary thyroid cancer often develops in patients with somatic or germline mutations in RET . Selpercatinib is a novel RET inhibitor. In a phase 1–2 trial, a…”
Get full text